Resources

In this Exclusive Interview, Aaron Vinik, Diabetes in Control board member, talks with Diabetes in Control Publisher Steve Freed during the AACE 2018 convention in Boston, MA about the current position on the protein INGAP and the work to stop the body's attack on beta cells, which hinders advancement in this research. He also shares on balancing the body's autonomic nervous system.

In part 1 of this Exclusive Interview, Aaron Vinik talks with Diabetes in Control Publisher Steve Freed during the AACE 2018 convention in Boston, MA about the latest on his INGAP research and understanding the role of the brain in diabetes.

In part 2 of this Exclusive Interview, Aaron Vinik talks with Diabetes in Control Publisher Steve Freed during the AACE 2018 convention in Boston, MA about this year's exciting breakthroughs and reinforcing the importance of reducing cardio events by going beyond the focus on glucose.

In part 3 of this Exclusive Interview, Aaron Vinik talks with Diabetes in Control Publisher Steve Freed during the AACE 2018 convention in Boston, MA about the importance of knowing the resting heart rate and how it impacts the rest of the body.

In part 4 of this Exclusive Interview, Aaron Vinik talks with Diabetes in Control Publisher Steve Freed during the AACE 2018 convention in Boston, MA about the complexity and simplicity of measuring the balance of a patient's autonomic nervous system.

In part 5 of this Exclusive Interview, Aaron Vinik talks with Diabetes in Control Publisher Steve Freed during the AACE 2018 convention in Boston, MA about the best patients to whom to prescribe SGLT-2s or other medication with the use of the correct risk calculator.

In part 6, the conclusion of this Exclusive Interview, Aaron Vinik talks with Diabetes in Control Publisher Steve Freed during the AACE 2018 convention in Boston, MA about the possibility of using available medications to restore the body's balance as well as his thoughts on a possible tool to help with the prescribing of medications.

Researchers discover safe and effective therapy to reduce insulin requirements and hypoglycemic episodes in adult subjects with recent onset type 1.

Drug shown to reduce risk of CV death or hospitalization for heart failure in adults with CV disease and type 2 diabetes, irrespective of their CV risk at study start.

According to new study, African Americans with type 2 diabetes mellitus (T2DM) have a higher risk of developing pancreatic cancer relative to other ethnic groups.